Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytosorbents Corp (CTSO) and Cutera (CUTR).
Cytosorbents Corp (CTSO)
In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Cytosorbents Corp, with a price target of $18. The company’s shares closed yesterday at $9.65.
McCarthy wrote:
“Cytosorbents reported 3Q18 with $5.1M in product sales; while this represents a 48% increase from $3.4M in 3Q17, revenues were down slightly on a sequential basis from $5.2M in 2Q18. Total revenue, including grant revenue was $5.7M, which was essentially flat sequentially. The company reported a net loss of $3M and ended the period with $24.9M in cash, which should provide runway to 2H20.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 5.1% and a 39.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Cytosorbents Corp has an analyst consensus of Strong Buy, with a price target consensus of $16.50, which is a 71.0% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $15 price target.
.
See today’s analyst top recommended stocks >>
Cutera (CUTR)
Maxim Group analyst Anthony Vendetti maintained a Hold rating on Cutera today. The company’s shares closed yesterday at $21.25, close to its 52-week low of $19.11.
Vendetti wrote:
“Market close, CUTR reported slightly better-than-expected 3Q18 results (compared to the preannouncement), including higher non- GAAP EPS and a narrower GAAP loss per share. As expected, the company lowered its 2018 guidance for non-GAAP EPS and adjusted EBITDA. We previously lowered our estimates in anticipation of these reductions when CUTR reported weaker-than-expected preliminary 3Q18 revenue and reduced its 2018 revenue guidance on October 4, 2018. We are introducing quarterly estimates for 2019.”
According to TipRanks.com, Vendetti is a 5-star analyst with an average return of 11.2% and a 55.2% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Restoration Robotics Inc, and Xtant Medical Holdings.
Currently, the analyst consensus on Cutera is a Moderate Buy with an average price target of $39.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
